Y-27632 Dihydrochloride: Selective ROCK1/2 Inhibitor for Cell and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a potent, selective small-molecule inhibitor of ROCK1 and ROCK2 kinases, exhibiting an IC50 of ~140 nM for ROCK1 and a Ki of 300 nM for ROCK2 under standard in vitro conditions (APExBIO). It disrupts Rho-mediated cytoskeletal stress fiber formation, modulates cell cycle progression, and inhibits cytokinesis. This compound is highly soluble in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), and water (≥52.9 mg/mL), facilitating diverse experimental workflows. Y-27632 has demonstrated efficacy in reducing tumor invasion and metastasis in murine models, and enhances stem cell viability in vitro. It is a reference compound for dissecting the Rho/ROCK signaling pathway and related cellular mechanisms (Ren et al., 2025).

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases that regulate actin cytoskeleton dynamics, cell contractility, and cell cycle transitions. The Rho/ROCK pathway is involved in stress fiber formation, tight junction integrity, and cellular motility (Ren et al., 2025). Dysregulation of ROCK activity contributes to cancer cell invasion, metastasis, and aberrant cytokinesis. In viral pathogenesis, ROCK1 interacts with viral proteins (e.g., MVC VP2) to promote host cell entry and disrupt tight junctions, illustrating the pathway's broad biological relevance (Ren et al., 2025).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride binds to the catalytic domains of ROCK1 and ROCK2, preventing ATP-dependent phosphorylation of substrates such as myosin light chain 2 (MLC2). This inhibition results in reduced actomyosin contractility and dismantling of stress fibers. In cell-based assays, Y-27632 blocks RhoA/ROCK1 signaling, preserving tight junctions and restricting pathological cell permeability (Ren et al., 2025). Its selectivity exceeds 200-fold against other kinases (e.g., PKC, MLCK, PAK), minimizing off-target effects in typical concentrations (0.1–10 μM). The compound's effects are rapid and reversible upon washout. Y-27632 also modulates cell cycle progression from G1 to S phase and inhibits cytokinesis by interfering with contractile ring formation. This mechanism underpins its utility in studies of cell proliferation, stem cell maintenance, and tumor invasion (APExBIO).

Evidence & Benchmarks

• Direct inhibition of ROCK1 catalytic domain by Y-27632 confirmed via mass spectrometry and immunoprecipitation (Ren et al., 2025, https://doi.org/10.3390/microorganisms13030695).
• IC50 for ROCK1: 140 nM; Ki for ROCK2: 300 nM under standard in vitro kinase assay conditions (APExBIO, https://www.apexbt.com/y-27632-dihydrochloride.html).
• Over 200-fold selectivity versus PKC, MLCK, and PAK kinases in comparative enzymatic assays (APExBIO, https://www.apexbt.com/y-27632-dihydrochloride.html).
• In vitro, Y-27632 reduces prostatic smooth muscle cell proliferation in a concentration-dependent manner (APExBIO, https://www.apexbt.com/y-27632-dihydrochloride.html).
• In vivo, Y-27632 decreases tumor invasion and metastasis in murine models (APExBIO, https://www.apexbt.com/y-27632-dihydrochloride.html).
• ROCK1 inhibition by Y-27632 blocks MVC-induced tight junction disruption and occludin translocation in WRD canine cells (Ren et al., 2025, https://doi.org/10.3390/microorganisms13030695).

Compared to previous coverage of Y-27632 in viral pathogenesis, this article delves deeper into kinase selectivity and translational cancer applications. For a workflow-focused guide, see Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Advanced Research, which provides stepwise protocols; our review provides updated selectivity and in vivo efficacy data. For broader translational perspectives, Strategic ROCK Inhibition with Y-27632 Dihydrochloride contextualizes clinical promise, whereas this article focuses on peer-reviewed mechanistic evidence.

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is employed in:

• Cancer research: Suppresses invasion and metastasis by modulating actomyosin contractility.
• Stem cell viability: Enhances survival during dissociation and passaging of human pluripotent stem cells.
• Cytoskeletal studies: Dissects Rho-mediated stress fiber and tight junction regulation.
• Cell proliferation assays: Modulates G1/S phase progression and cytokinesis.
• Viral entry research: Inhibits viral protein-induced tight junction disruption (e.g., MVC VP2-ROCK1 interaction).

Common Pitfalls or Misconceptions

• Y-27632 is not an inhibitor of upstream RhoA GTPase activity; it specifically targets ROCK1/2 catalytic domains.
• Off-target effects may occur at concentrations >10 μM, especially in non-mammalian models.
• Y-27632 cannot reverse established actin cytoskeletal defects caused by non-ROCK pathways.
• Long-term use (>72 hours) in cell culture may affect cell phenotype unrelated to ROCK inhibition.
• It is not suitable for in vivo use without pharmacokinetic validation due to rapid clearance in some animal models.

Workflow Integration & Parameters

Y-27632 dihydrochloride (APExBIO, Cat#A3008) is supplied as a solid and should be stored desiccated at 4°C or below. For stock solution preparation, dissolve in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), or water (≥52.9 mg/mL); warming to 37°C or using an ultrasonic bath increases solubility. Stocks are stable below -20°C for several months, but avoid repeated freeze-thaw cycles and long-term storage of working solutions. Typical in vitro concentrations: 1–10 μM; in vivo dosing requires pharmacokinetic optimization. Use sterile filtration prior to cell-based assays. For stem cell applications, Y-27632 is usually added during cell dissociation and removed after 24–48 hours. For mechanistic studies, titrate to minimal effective concentration to reduce off-target effects. Refer to the A3008 kit for detailed protocol recommendations.

Conclusion & Outlook

Y-27632 dihydrochloride remains a reference compound for selective modulation of the Rho/ROCK pathway, with applications spanning cancer biology, stem cell research, and viral pathogenesis. Its high selectivity and robust solubility support diverse experimental designs. Recent studies, such as Ren et al. (2025), underscore its utility for dissecting kinase-mediated tight junction regulation and highlight emerging antiviral strategies targeting ROCK1 (Ren et al., 2025). As research advances, Y-27632 will continue to serve as a standard for benchmarking novel inhibitors and elucidating ROCK-dependent mechanisms. For up-to-date usage guidelines and product specifications, consult APExBIO.